Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Amortizatization of Intangibles: 2014-2025

Historic Amortizatization of Intangibles for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to $636,000.

  • CytomX Therapeutics' Amortizatization of Intangibles fell 47.87% to $636,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 66.31%. This contributed to the annual value of $5.3 million for FY2024, which is 28.41% down from last year.
  • Per CytomX Therapeutics' latest filing, its Amortizatization of Intangibles stood at $636,000 for Q3 2025, which was up 60.20% from $397,000 recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Amortizatization of Intangibles registered a high of $2.2 million during Q4 2023, and its lowest value of -$141,000 during Q1 2021.
  • In the last 3 years, CytomX Therapeutics' Amortizatization of Intangibles had a median value of $1.4 million in 2024 and averaged $1.3 million.
  • In the last 5 years, CytomX Therapeutics' Amortizatization of Intangibles slumped by 211.02% in 2021 and then spiked by 6,083.33% in 2023.
  • Over the past 5 years, CytomX Therapeutics' Amortizatization of Intangibles (Quarterly) stood at $15,000 in 2021, then spiked by 140.00% to $36,000 in 2022, then spiked by 6,083.33% to $2.2 million in 2023, then slumped by 64.65% to $787,000 in 2024, then slumped by 47.87% to $636,000 in 2025.
  • Its Amortizatization of Intangibles was $636,000 in Q3 2025, compared to $397,000 in Q2 2025 and $454,000 in Q1 2025.